Navigation Links
TCT 2010 late breaking trials to have impact on practice of interventional cardiology
Date:9/7/2010

-Eluting Stents: The ISAR TEST-4 trial will feature angiographic and clinical 2 year results from a randomized comparison of everolimus-eluting stents versus sirolimus-eluting stents. The study will shed important light on comparative outcomes of the leading first- and second generation drug-eluting stents as well as provide direct insight into the relative late performance characteristics of both devices.

  • Drug-Eluting Stents: The DES-BTK trial is a prospective, double-blind randomized trial comparing a polymer-free sirolimus-eluting stent with a bare-metal stent in patients with infrapopliteal disease.

  • Venous Thromboembolism: TORPEDO is the first prospective randomized controlled trial of the efficacy of percutaneous endovenous intervention in the reduction of venous thromboembolism and post-thrombotic syndrome, 2 common complications of deep venous thrombosis.

  • Restenosis Therapy: The BLAST study will provide important insights on the safety and effectiveness of LABR-312 as a systemic anti-restenosis therapy after vascular intervention in patients with coronary stenoses. The novel use of this monocyte-specific inhibitor and the quantitative correlation of angiographic and clinical effects along a biological continuum of cellular modulation may change the paradigm of concomitant drug therapy to prevent restenosis.

    SATURDAY, SEPTEMBER 25

    • Drug-Eluting Stents: ISAR-TEST-5 is a prospective, randomized trial of the polymer-free sirolimus/probucol-eluting stents compared to zotarolimus-eluting stents in patients with coronary artery disease stents after 1 year.

    • Pharmaceutical Therapy; Drug-Eluting Stents: HORIZONS-AMI is the largest completed randomized trial of different pharmacologic regimens and stent types in heart attack patients. At 1 year, bivalirudin alone compared to heparin plus glycoprotein IIb/IIIa inhibitors resulted in significantly reduced rates of major bleeding and mo
      '/>"/>

    Contact: Judy Romero
    jromero@crf.org
    Cardiovascular Research Foundation
    Source:Eurekalert

    Page: 1 2 3 4

    Related medicine news :

    1. CRF announces late breaking trials and first report investigations to be presented at TCT 2010
    2. The Institute for Health Metrics and Evaluation selects DatStat as the foundation for ground breaking healthcare project
    3. Enterprise Architecture -- Breaking Away From The Pack
    4. American Association for Cancer Research has Record-breaking Registration at 101st Annual Meeting
    5. Ground-breaking study to improve quality of life and outcomes for kids born with heart defect
    6. World Record-Breaking CPR and AED Training Event at the 2010 National Scout Jamboree
    7. Breaking down barriers in brain imaging
    8. Second volume of groundbreaking Emerging Model Organisms series is released
    9. Groundbreaking MS research to be presented at American Academy of Neurology Annual Meeting
    10. LASIK Surgeons, Plastic Surgeons, Cosmetic Dentists and other Cash Paid Medical Specialists Brought Together for Groundbreaking Webinar Series
    11. Business Book Author is Breaking All the Rules and Utilizing Social Media in a Way that Has Never Been Done Before
  • Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/24/2014)... with high-throughput data generated by breast cancer biologists ... computational method to determine how gene networks are ... as they respond to potential cancer therapy agents., ... each other in laboratory-grown cells is described in ... PLOS Computational Biology . , The method ...
    (Date:7/24/2014)... who received the Human Papillomavirus Vaccination (HPV) even ... abnormal Pap test results than those who were ... Sexually Transmitted Diseases . , Researchers ... School of Medicine conducted a cross-sectional study of ... cervical cytology testing. HPV status and demographic and ...
    (Date:7/24/2014)... CA (PRWEB) July 24, 2014 ... Optometric Association (AOA) and the Entertainment Industries Council ... the TV series American Horror Story on a ... bring the dramatic realities of illegal and unsafe ... campaign, which has already reached tens-of-thousands, is now ...
    (Date:7/24/2014)... Annual National Venous Interventional Summit is available at: ... established Venous Endovascular Interventional Strategies group comprised of ... to provide a "How To" meeting for cardiologists ... advancing their knowledge and skills in venous interventions ... comprehensive venous interventional program. Topics at this year,s ...
    (Date:7/24/2014)... the strategy adopted by tumor cells to transform into ... a gloomy prognosis. Managing to block the metastasis or, ... step towards the fight against cancer. Researchers at Universit ... on models of human tumors in mice. The ... July in the prestigious journal Cell Reports . ...
    Breaking Medicine News(10 mins):Health News:Gene changes in breast cancer cells pinpointed with new computational method 2Health News:Gene changes in breast cancer cells pinpointed with new computational method 3Health News:Optometric Professionals Team with Hollywood for Second Installment of Video Campaign 2Health News:Optometric Professionals Team with Hollywood for Second Installment of Video Campaign 3Health News:Optometric Professionals Team with Hollywood for Second Installment of Video Campaign 4Health News:Preliminary agenda available for 4th VEINS Conference to be held October 9-12 in Chicago 2Health News:A world first: Researchers identify a treatment that prevents tumor metastasis 2
    ... June 17 ANSi Consulting (ANSi) proudly announces its ... South Jersey,s 25 fastest-growing private companies in the eight-county ... on June 11th, held at The Merion in Cinnaminson, ... (ANSi,s very first company award) on behalf of all ...
    ... 15 Years of Healthcare Experience to Growing North Texas Company ... Faro joins Dallas-based North American Spine ... years of healthcare experience, specializing in the development, growth and ... role, Faro will lead North American Spine,s efforts to build ...
    ... announced today that it has received approval from the U.S. ... Filled Capsules, a new treatment option indicated for relief of ... age or older). , , "Zipsor is a drug ... Officer of Xanodyne. "It is the first NSAID to ...
    ... Applied Medical, a new generation medical company, was ... healthcare alliance ,s first Innovation Celebration, an annual ... industry suppliers committed to innovation and improving patient outcomes. ... that bring a positive impact to healthcare delivery. The ...
    ... revealed that despite the drooping economy Scots men are opting ... moob removal surgery and finally getting their insecurities off their ... Cosmetic Surgery Group has revealed that despite the drooping economy ... by booking in for moob removal surgery and finally getting ...
    ... Surgical Company (Nasdaq: STAA ), a leading ... today announced the approval of the KS-Ni Preloaded Silicone ... , , The KS-Ni Preloaded Silicone IOL Injector ... silicone IOL through an incision size of 2.6 mm ...
    Cached Medicine News:Health News:ANSi Answers When Awarded the Philadelphia Business Journal's Prestigious 2009 South Jersey 25 Accolade 2Health News:Stephen D. Faro Joins North American Spine as Chief Operating Officer 2Health News:Stephen D. Faro Joins North American Spine as Chief Operating Officer 3Health News:Xanodyne Receives Approval From the U.S. Food and Drug Administration for ZIPSOR(TM) (diclofenac potassium) Liquid Filled Capsules 2Health News:Applied Medical Selected by the Premier Healthcare Alliance to Highlight Commitment to Healthcare Quality Improvement, Innovation 2Health News:Applied Medical Selected by the Premier Healthcare Alliance to Highlight Commitment to Healthcare Quality Improvement, Innovation 3Health News:Scots Men Get the Issue of Moobs Off Their Chests in Time for Summer - Male Surgery in Scotland Sees 80 Per Cent Growth 2Health News:Scots Men Get the Issue of Moobs Off Their Chests in Time for Summer - Male Surgery in Scotland Sees 80 Per Cent Growth 3Health News:STAAR Surgical Receives Japanese Clearance for the KS-Ni Preloaded IOL Injector System 2Health News:STAAR Surgical Receives Japanese Clearance for the KS-Ni Preloaded IOL Injector System 3
    (Date:7/24/2014)... July 24, 2014  To help health care ... that could impact patient care and the bottom ... Watch , "Innovations in Cardiovascular Devices."  ... guidance and details on promising new technologies that ... understand how these options impact the supply chain.   ...
    (Date:7/24/2014)... 2014 Valeant Pharmaceuticals International, Inc. ("Valeant") ... that it has filed a detailed complaint with ... Inc.,s (NYSE: AGN ) apparent attempts ... market price of Valeant,s common shares by continuing ... business despite Valeant,s public statements correcting this misinformation. ...
    (Date:7/24/2014)... 24, 2014 , Revenues from continuing ... , Adjusted diluted EPS from continuing operations of $1.08, up ... continuing operations of $0.92, 7% below prior year , ... year , Full year 2014 revenues now expected to ... previously , Full year 2014 adjusted diluted EPS range ...
    Breaking Medicine Technology:New Novation CV Watch Shows Recent Technology Innovations Could Drive Cardiovascular Product Costs Up by as Much as 35 Percent 2New Novation CV Watch Shows Recent Technology Innovations Could Drive Cardiovascular Product Costs Up by as Much as 35 Percent 3Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergan's False And Misleading Statements 2Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergan's False And Misleading Statements 3Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergan's False And Misleading Statements 4Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergan's False And Misleading Statements 5Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergan's False And Misleading Statements 6Quest Diagnostics Reports Second Quarter 2014 Financial Results 2Quest Diagnostics Reports Second Quarter 2014 Financial Results 3Quest Diagnostics Reports Second Quarter 2014 Financial Results 4Quest Diagnostics Reports Second Quarter 2014 Financial Results 5Quest Diagnostics Reports Second Quarter 2014 Financial Results 6Quest Diagnostics Reports Second Quarter 2014 Financial Results 7Quest Diagnostics Reports Second Quarter 2014 Financial Results 8Quest Diagnostics Reports Second Quarter 2014 Financial Results 9Quest Diagnostics Reports Second Quarter 2014 Financial Results 10Quest Diagnostics Reports Second Quarter 2014 Financial Results 11Quest Diagnostics Reports Second Quarter 2014 Financial Results 12Quest Diagnostics Reports Second Quarter 2014 Financial Results 13Quest Diagnostics Reports Second Quarter 2014 Financial Results 14Quest Diagnostics Reports Second Quarter 2014 Financial Results 15Quest Diagnostics Reports Second Quarter 2014 Financial Results 16Quest Diagnostics Reports Second Quarter 2014 Financial Results 17Quest Diagnostics Reports Second Quarter 2014 Financial Results 18Quest Diagnostics Reports Second Quarter 2014 Financial Results 19Quest Diagnostics Reports Second Quarter 2014 Financial Results 20Quest Diagnostics Reports Second Quarter 2014 Financial Results 21Quest Diagnostics Reports Second Quarter 2014 Financial Results 22
    ... Bacterin International Holdings, Inc. (NYSE Amex: ... bone graft material and antimicrobial coatings for medical applications, reported ... Financial Highlights: Q2 2011 vs. Q2 2010 ... seventh consecutive quarter of record revenues. Net loss improved ...
    ... BEACH, Calif., Aug. 11, 2011 Diversified Medical Equipment ... medical supply company servicing the long-term care and home care ... medical supply store has more than doubled in size ... the company,s portfolio, www.dmes.com has grown to become ...
    Cached Medicine Technology:Bacterin Second Quarter 2011 Revenues up 135% Over Prior Year, Driving First Positive EBITDA Quarter 2Bacterin Second Quarter 2011 Revenues up 135% Over Prior Year, Driving First Positive EBITDA Quarter 3Bacterin Second Quarter 2011 Revenues up 135% Over Prior Year, Driving First Positive EBITDA Quarter 4Bacterin Second Quarter 2011 Revenues up 135% Over Prior Year, Driving First Positive EBITDA Quarter 5Bacterin Second Quarter 2011 Revenues up 135% Over Prior Year, Driving First Positive EBITDA Quarter 6Bacterin Second Quarter 2011 Revenues up 135% Over Prior Year, Driving First Positive EBITDA Quarter 7Bacterin Second Quarter 2011 Revenues up 135% Over Prior Year, Driving First Positive EBITDA Quarter 8Bacterin Second Quarter 2011 Revenues up 135% Over Prior Year, Driving First Positive EBITDA Quarter 9DMES, Inc. Announces 100 Percent Growth for Online Medical Supply Store 2
    The Surgiflex WAVE XP couples the state-of-the-art Surgiflex WAVE Probe with the convenience of a truly portable battery-powered pump....
    Stryker Endoscopy has combined a standardized pressurizing system with an advanced hand piece design that is lightweight and compact in order to streamline laparoscopic procedures....
    ... specifically to disintegrate renal and ... state-of-the-art technology in a compact ... efficient and affordable lithotripsy system. ... level of clinical results for ...
    ...
    Medicine Products: